RT Journal Article SR Electronic T1 Promoter methylation of Wnt/β-Catenin signal inhibitor TMEM88 is associated with unfavorable prognosis of non-small cell lung cancer JF Cancer Biology and Medicine JO Cancer Biol Med FD China Anti-Cancer Association SP 377 OP 386 DO 10.20892/j.issn.2095-3941.2017.0061 VO 14 IS 4 A1 Rongna Ma A1 Nannan Feng A1 Xiao Yu A1 Hongyan Lin A1 Xiaohong Zhang A1 Oumin Shi A1 Huan Zhang A1 Shuo Zhang A1 Lei Li A1 Min Zheng A1 Ming Gao A1 Herbert Yu A1 Biyun Qian YR 2017 UL http://www.cancerbiomed.org/content/14/4/377.abstract AB Objective: Recent research has indicated that altered promoter methylation of oncogenes and tumor suppressor genes is an important mechanism in lung cancer development and progression. In this study, we investigated the association between promoter methylation of TMEM88, a possible inhibitor of the Wnt/β-Catenin signaling, and the survival of patients with non-small cell lung cancer (NSCLC). Methods: Twelve pairs of tumor and adjacent non-tumor samples were used for microarray analyses of DNA methylation and gene expression. For validation, more than two hundred additional samples were analyzed for methylation using bisulfite pyrosequencing and for gene expression using qRT-PCR. Then the cell function were tested by wound healing, transwell, CCK8 and cell cycle assay. Results: Our analysis of patient specimens showed that TMEM88 methylation was higher in NSCLC tumors (82.2% ± 10.3, P < 0.01) compared with the adjacent normal tissues (65.9% ± 7.2). The survival analysis revealed that patients with high TMEM88 methylation had a shorter overall survival (46 months) compared with patients with low TMEM88 methylation (>56 months;P=0.021). In addition, we found that demethylation treatment could inhibit tumor cell proliferation, migration, and invasion, which was supportive of an association between methylation and survival. Conclusions: Based on these consistent observations, we concluded that TMEM88 may play an important role in NSCLC progression and that promoter methylation of TMEM88 may serve as a biomarker for NSCLC prognosis and treatment.